Table of Contents
Hepatitis Research and Treatment
Volume 2014, Article ID 296958, 5 pages
Research Article

Prevalence and Seroincidence of Hepatitis B and Hepatitis C Infection in High Risk People Who Inject Drugs in China and Thailand

1Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA
2Guangxi Center for Disease Control and Prevention, Nanning 530028, China
3Xinjiang Center for Disease Control and Prevention, Urumqi 83001, China
4Research Institute for Health Sciences, Chiang Mai University, Chiang Mai 50200, Thailand
5Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
6Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
7State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing 102206, China
8University of Pennsylvania, Philadelphia, PA 19104, USA

Received 16 October 2013; Revised 25 February 2014; Accepted 25 February 2014; Published 27 March 2014

Academic Editor: Annarosa Floreani

Copyright © 2014 J. Brooks Jackson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Aceijas and T. Rhodes, “Global estimates of prevalence of HCV infection among injecting drug users,” International Journal of Drug Policy, vol. 18, no. 5, pp. 352–358, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. L. J. Liu and L. Wei, “Epidemiology of hepatitis C virus,” Infectious Disease Information, vol. 20, pp. 261–264, 2007 (Chinese). View at Google Scholar
  3. V. Verachai, T. Phutiprawan, A. Theamboonlers et al., “Prevalence and genotypes of hepatitis C virus infection among drug addicts and blood donors in Thailand,” Southeast Asian Journal of Tropical Medicine and Public Health, vol. 33, no. 4, pp. 849–851, 2002. View at Google Scholar · View at Scopus
  4. G. Greub, B. Ledergerber, M. Battegay et al., “Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The swiss HIV cohort study,” The Lancet, vol. 356, no. 9244, pp. 1800–1805, 2000. View at Google Scholar · View at Scopus
  5. F. M. Lu, T. Li, S. Liu, and H. Zhuang, “Epidemiology and prevention of hepatitis B virus infection in China,” Journal of Viral Hepatitis, vol. 17, supplement 1, pp. 4–9, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Sungkanuparph, A. Vibhagool, W. Manosuthi et al., “Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study,” Journal of the Medical Association of Thailand, vol. 87, no. 11, pp. 1349–1354, 2004. View at Google Scholar · View at Scopus
  7. H. M. Chun, M. P. Roediger, K. H. Hullsiek et al., “Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters,” Journal of Infectious Diseases, vol. 205, no. 2, pp. 185–193, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Metzger, D. Donnell, B. Jackson et al., “One year of counseling supported buprenorphine-naloxone treatment for HIV prevention in opiate dependent injecting drug users showed efficacy in reducing opiate use and injection frequency: HPTN 058 in Thailand and China. Abstract THPE191,” in Proceedings of the 19th International AIDS Conference, Washington, DC, USA, July 2012.
  9. C. L. Fan, L. Wei, D. Jiang et al., “Spontaneous viral clearance after 6–21 years of hepatitis B and C viruses coinfection in high HBV endemic area,” World Journal of Gastroenterology, vol. 9, no. 9, pp. 2012–2016, 2003. View at Google Scholar · View at Scopus